<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p89" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_89{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_89{left:341px;bottom:30px;}
#t3_89{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_89{left:377px;bottom:30px;}
#t5_89{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_89{left:540px;bottom:30px;}
#t7_89{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_89{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_89{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_89{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_89{left:285px;bottom:827px;letter-spacing:-0.29px;}
#tc_89{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_89{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_89{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_89{left:1130px;bottom:28px;letter-spacing:0.17px;}
#tg_89{left:36px;bottom:148px;}
#th_89{left:46px;bottom:142px;letter-spacing:0.13px;}
#ti_89{left:261px;bottom:142px;}
#tj_89{left:36px;bottom:131px;}
#tk_89{left:42px;bottom:125px;letter-spacing:0.13px;word-spacing:-0.06px;}
#tl_89{left:310px;bottom:125px;}
#tm_89{left:36px;bottom:114px;}
#tn_89{left:42px;bottom:108px;letter-spacing:0.11px;word-spacing:0.01px;}
#to_89{left:36px;bottom:778px;letter-spacing:0.29px;word-spacing:-0.17px;}
#tp_89{left:533px;bottom:778px;letter-spacing:-0.1px;}
#tq_89{left:894px;bottom:778px;}
#tr_89{left:36px;bottom:504px;letter-spacing:-0.1px;}
#ts_89{left:258px;bottom:504px;letter-spacing:-0.1px;}
#tt_89{left:393px;bottom:511px;}
#tu_89{left:518px;bottom:514px;letter-spacing:-0.09px;}
#tv_89{left:518px;bottom:496px;letter-spacing:-0.09px;}
#tw_89{left:659px;bottom:503px;letter-spacing:-0.07px;}
#tx_89{left:791px;bottom:514px;letter-spacing:-0.14px;word-spacing:-0.11px;}
#ty_89{left:791px;bottom:496px;letter-spacing:-0.1px;}
#tz_89{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_89{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_89{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_89{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_89{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_89{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_89{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_89{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_89{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s8_89{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s9_89{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.sa_89{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sb_89{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts89" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg89Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg89" style="-webkit-user-select: none;"><object width="1210" height="935" data="89/89.svg" type="image/svg+xml" id="pdf89" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_89" class="t s0_89">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_89" class="t s1_89">® </span>
<span id="t3_89" class="t s0_89">(NCCN </span>
<span id="t4_89" class="t s1_89">® </span>
<span id="t5_89" class="t s0_89">), All rights reserved. NCCN Guidelines </span>
<span id="t6_89" class="t s1_89">® </span>
<span id="t7_89" class="t s0_89">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_89" class="t s2_89">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_89" class="t s2_89">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_89" class="t s3_89">NCCN Guidelines Version 4.2024 </span>
<span id="tb_89" class="t s3_89">Mucosal Melanoma </span>
<span id="tc_89" class="t s4_89">NCCN Guidelines Index </span>
<span id="td_89" class="t s4_89">Table of Contents </span>
<span id="te_89" class="t s4_89">Discussion </span>
<span id="tf_89" class="t s5_89">MM-4 </span>
<span id="tg_89" class="t s6_89">h </span>
<span id="th_89" class="t s7_89">Principles of Surgery (SURG-A)</span><span id="ti_89" class="t s8_89">. </span>
<span id="tj_89" class="t s6_89">i </span>
<span id="tk_89" class="t s7_89">Principles of Radiation Therapy (MM-A)</span><span id="tl_89" class="t s8_89">. </span>
<span id="tm_89" class="t s6_89">l </span>
<span id="tn_89" class="t s8_89">High-risk: adverse pathologic features: &gt;2 nodes, single node &gt;3 cm, extranodal extension, recurrence in nodal basin after previous surgery. </span>
<span id="to_89" class="t s5_89">PRIMARY THERAPY FOR OCCULT PRIMARY- MELANOMA (</span><span id="tp_89" class="t s9_89">also see NCCN Guidelines for Occult Primary</span><span id="tq_89" class="t s5_89">) </span>
<span id="tr_89" class="t s5_89">Nodal basin </span><span id="ts_89" class="t s5_89">Nodal dissection </span>
<span id="tt_89" class="t sa_89">h </span>
<span id="tu_89" class="t s5_89">± RT to nodal basin for </span>
<span id="tv_89" class="t s5_89">high-risk features </span>
<span id="tw_89" class="t sa_89">i,l </span>
<span id="tx_89" class="t s5_89">± Adjuvant systemic therapy, per </span>
<span id="ty_89" class="t s9_89">NCCN Guidelines for Melanoma: Cutaneous </span>
<span id="tz_89" class="t sb_89">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
